Efficacy of aerosol inhalation of tiotropium and symbicort on FeNO, total IgE in serum, inflammatory factors and lung function in patients with asthma-chronic obstructive pulmonary disease overlap syndrome

Xu Feng, Hongjie Guo
{"title":"Efficacy of aerosol inhalation of tiotropium and symbicort on FeNO, total IgE in serum, inflammatory factors and lung function in patients with asthma-chronic obstructive pulmonary disease overlap syndrome","authors":"Xu Feng, Hongjie Guo","doi":"10.3760/CMA.J.ISSN.1674-4756.2020.03.026","DOIUrl":null,"url":null,"abstract":"Objective \nTo observe the efficacy of aerosol inhalation of tiotropium and symbicort on FeNO, total IgE in serum, inflammatory factors and lung function in patients with asthma-chronic obstructive pulmonary disease overlap syndrome(ACOS). \n \n \nMethods \nThe clinical data of 124 ACOS patients admitted to the First Affiliated Hospital of Nanyang Medical College from January 2017 to March 2019 were retrospectively analyzed. According to the treatment methods, the patients were divided into observation group and control group, with 62 cases in each group. Patients in control group was given symbicort inhalation therapy on the basis of conventional symptomatic treatment, and patients in observation group was given tiotropium inhalation therapy on the basis of treatment of control group. All patients were continuously treated for 12 weeks. The (FeNO), serum total IgE, airway-related inflammatory factors, such as leukotriene B4 (LTB4), interleukin-6 (IL-6), myeloperoxidase (MPO), 8-isoprostanes (8-isoPG), lung function indicators, such as forced expiratory volume in 1 second (FEV1), forced vital capacity (FVC), FEV1/FVC value and symptoms scores, such as Asthma Control Test (ACT), chronic obstructive pulmonary disease (COPD) Assessment Test (CAT) were compared between the two groups, and the occurrence of adverse effects was monitored. \n \n \nResults \nAfter treatment, the levels of FeNO and serum total IgE in the two groups were significantly lower than those before treatment (P 0.05. \n \n \nConclusions \nCompared with symbicort inhalation therap, tiotropium combined with symbicort inhalation therapy for patients with ACOS can improve the allergic reactions, airway inflammatory response, lung function and symptoms without increasing incidence of adverse effects. \n \n \nKey words: \nAsthma-chronic obstructive pulmonary disease overlap syndrome; Tiotropium; Glucocorticoid; Fractional exhaled nitric oxide; Serum total immunoglobin E; Lung function","PeriodicalId":9667,"journal":{"name":"Central Plains Medical Journal","volume":"23 1","pages":"97-101"},"PeriodicalIF":0.0000,"publicationDate":"2020-02-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Central Plains Medical Journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3760/CMA.J.ISSN.1674-4756.2020.03.026","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Objective To observe the efficacy of aerosol inhalation of tiotropium and symbicort on FeNO, total IgE in serum, inflammatory factors and lung function in patients with asthma-chronic obstructive pulmonary disease overlap syndrome(ACOS). Methods The clinical data of 124 ACOS patients admitted to the First Affiliated Hospital of Nanyang Medical College from January 2017 to March 2019 were retrospectively analyzed. According to the treatment methods, the patients were divided into observation group and control group, with 62 cases in each group. Patients in control group was given symbicort inhalation therapy on the basis of conventional symptomatic treatment, and patients in observation group was given tiotropium inhalation therapy on the basis of treatment of control group. All patients were continuously treated for 12 weeks. The (FeNO), serum total IgE, airway-related inflammatory factors, such as leukotriene B4 (LTB4), interleukin-6 (IL-6), myeloperoxidase (MPO), 8-isoprostanes (8-isoPG), lung function indicators, such as forced expiratory volume in 1 second (FEV1), forced vital capacity (FVC), FEV1/FVC value and symptoms scores, such as Asthma Control Test (ACT), chronic obstructive pulmonary disease (COPD) Assessment Test (CAT) were compared between the two groups, and the occurrence of adverse effects was monitored. Results After treatment, the levels of FeNO and serum total IgE in the two groups were significantly lower than those before treatment (P 0.05. Conclusions Compared with symbicort inhalation therap, tiotropium combined with symbicort inhalation therapy for patients with ACOS can improve the allergic reactions, airway inflammatory response, lung function and symptoms without increasing incidence of adverse effects. Key words: Asthma-chronic obstructive pulmonary disease overlap syndrome; Tiotropium; Glucocorticoid; Fractional exhaled nitric oxide; Serum total immunoglobin E; Lung function
雾化吸入噻托溴铵和共必可对哮喘-慢性阻塞性肺疾病重叠综合征患者血清总IgE、炎性因子和肺功能的影响
目的观察雾化吸入噻托溴铵和共必可对哮喘-慢性阻塞性肺疾病重叠综合征(ACOS)患者血清总IgE、FeNO、炎症因子及肺功能的影响。方法回顾性分析南洋医学院第一附属医院2017年1月至2019年3月收治的124例ACOS患者的临床资料。根据治疗方法将患者分为观察组和对照组,每组62例。对照组患者在常规对症治疗的基础上给予喜必可吸入治疗,观察组患者在对照组治疗的基础上给予噻托溴铵吸入治疗。所有患者均连续治疗12周。比较两组患者的FeNO、血清总IgE、气道相关炎症因子白三烯B4 (LTB4)、白介素-6 (IL-6)、髓过氧化物酶(MPO)、8-异前列腺素(8-isoPG)、1秒用力呼气量(FEV1)、用力肺活量(FVC)、FEV1/FVC值等肺功能指标以及哮喘控制试验(ACT)、慢性阻塞性肺疾病(COPD)评估试验(CAT)等症状评分。并监测不良反应的发生情况。结果治疗后,两组患者血清总IgE和FeNO水平均显著低于治疗前(P < 0.05)。结论与共bicort吸入治疗相比,噻托溴铵联合共bicort吸入治疗ACOS患者可改善过敏反应、气道炎症反应、肺功能和症状,且不增加不良反应的发生率。关键词:哮喘-慢性阻塞性肺疾病重叠综合征;Tiotropium;糖皮质激素;分式呼出一氧化氮;血清总免疫球蛋白E;肺功能
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信